medigraphic.com
Centro de Investigaciones Regionales Dr. Hideyo Noguchi, Universidad Autónoma de Yucatán

2006, Number 3

<< Back Next >>

Rev Biomed 2006; 17 (3)

Treatment of chronic liver disease induced by the hepatitis C virus: Molecular and cellular bases

León-Buitimea A, Leija-Salas A, Garrido-Fariña G, Reyes-Esparza J, Rodríguez-Fragoso L

Language: Spanish
References: 109
Page: 195-211
PDF size: 247.55 Kb.


ABSTRACT

In this review we analyse the currently available therapies for liver fibrosis induced by the hepatitis C virus. The present work is a review about the drugs employed at an experimental level and in the human beings for the treatment of chronic liver diseases in the last ten years. It also refers to the actual trends for solving this problem. The major obstacle to antifibrotic drug development is the slow evolution of fibrosis, which takes years or even decades in man. Recent insights into the molecular pathogenesis of hepatic fibrosis and the role of activated hepatic stellate cells provide hope for the future development of successful therapies.


REFERENCES

  1. Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F, Moyer LA. The prevalence of hepatitis C virus infection in the United States, 1998 through 1994. N Eng J Med 1999; 341:556-62.

  2. Liang TJ, Rehermann B, Sep LB, Hoofnagle JH. NIH Conference, Pathogenesis, natural history, treatment and prevention of hepatitis C. Ann Intern Med 2000; 132:296-305.

  3. Méndez-Sánchez N, Baptista-González H, Sánchez-Gómez RH, Bordes-Aznar J, Uribe M. The prevalence of hepatitis B and C in blood donors in a 3rd level hospital of Mexico City. Salud Publ Mex 1999; 41:475-8.

  4. Uribe M, Méndez-Sánchez N. Consenso nacional sobre hepatitis C. Rev Gastroenterol Mex 2002; 67:S7-8.

  5. National Institutes of Health Consensus Development Conference Statement: Management of Hepatitis C: 2002. Hepatology 2002; 36:S3-15.

  6. El-Serag HB, Mason AC, Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999; 340:745-50.

  7. Wong JB, McQuilan GM, McHutchinson JG, Poynard T. Estimating future hepatitis C morbidity, mortality and cost in the United States. Am J Public Health 2000; 90:1562-9.

  8. Valkova M. Hepatic fibrogenesis. Bratisl Lek Lis 2002; 103:76-85.

  9. Eng FJ, Friedman SL. Fibrogenesis. Am J Physiol Gastroenterol Liver Physiol 2000; 279:G7-11.

  10. Arthur MJ. Matrix degradation in liver: a role in injury and repair. Hepatology 1997; 26:1069-71.

  11. Gressner AM. Mediators of hepatic fibrogenesis. Hepatogastroenterology 1996; 43:92-103.

  12. Tsukamoto H. Cytokine regulation of hepatic stellate cells in liver fibrosis. Alcoholism Clin Exp Res 1999; 23:911-6.

  13. Friedman SL. Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J Biol Chem 2000; 275:2247-50.

  14. Schuppan D. Structure of extracellular matrix in normal and fibrotic liver: collagens and glycoproteins. Sem Liver Dis 1990; 10:1-10.

  15. Schuppan D, Gressner AM. Functions and metabolism of collagens and other extracellular matrix proteins. In: Bircher J, Benhamon JP, Rodes J, (Editores). Oxford Textbook of Clinical Hepatology, Oxforf University Press 1999. p. 381-406.

  16. Milani S, Herbst H, Schuppan D, Hahn EG, Stein H. In situ hybridization for procollagen types I, III and IV mRNA in normal and fibrotic rat liver: evidence for predominant expression in nonparenquimal liver cells. Hepatology 1989; 10:84-92.

  17. Neubauer K, Saile B, Ramadori G. Liver fibrosis and altered matrix synthesis. Can J Gastroenterol 2001; 15:187-93.

  18. Sato S, Leo MA, Lieber CS. Ultrastructural localization of type III procollagen in baboon liver. Am J Pathol 1986; 122:212-7.

  19. Friedman SL. The cellular basis of hepatic fibrosis. N Engl J med 1993; 328:1826-35.

  20. Brenner DA, Waterboer T, Choi SK. New aspects of hepatic fibrosis. J Hepatol 2000; 32:32-8.

  21. Gressner AM, Bachem MG. Molecular mechanisms of liver fibrogenesis – A homage to the role of activated fat storing cells. Digestion 1995; 56:335-46.

  22. Friedman SL. Liver fibrosis – from bench to bedside. J Hepatol 2003; 38:S38-53.

  23. Rai RM, Loffreda S, Karp CL, Yang SQ, Lin HZ, Diehl AM. Kupffer cells depletion abolishes induction of interleukin-10 and permits sustained overexpression of tumor necrosis factor alpha messenger RNA in the regeneration rat liver. Hepatology 1997; 25:889-95.

  24. Hellerbrand C, Stefanoc B, Giordano F, Burchardt ER, Brenner DA. The role of TGF β1 in initiating hepatic stellate cell activation in vivo. J hepatol 1999; 30:77-87.

  25. Dooley S, Delvoux B, Lahme B, Mangasser-Stephan K, Gressner AM. Modulation of transforming growth factor beta response and signaling during transdifferentiation of rat hepatic stellate cell to myofibroblasts. Hepatology 2000; 31:1094-106.

  26. Mallat A, Gallois C, Tao J, Habib A, Maclouf J, Mavier P, Preaux AM, Lotersztajn S. Platelet-derived growth factor-BB and trombin generate positive and negative signals for human hepatic stellate cell proliferation. Role of prostaglandin/cyclic AMP pathway and cross-talk with endothelin receptors. J Biol Chem 1998; 273:27300-5.

  27. Olaso E, Friedman SL. Molecular regulation of hepatic fibrosis. J Hepatol 1998; 29:836-42.

  28. Friedman SL. The virtuosity of hepatic stellate cells. Gastroenterol 1999; 117:1244-6.

  29. Hoffman C, Lahne B, Brenzel A, Gressner AM. The relation between hepatocellular damage and activation of fat storing cells proliferation in vitro. Inter Hepatol Commun 1994; 2:29-36.

  30. Friedman SL. Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J Biol Chem 2000; 275:2247-50

  31. Gressner AM. Cytokines and cellular crosstalk involved in the activation of fat-storing cells. J Hepatol 1995; 22:S28-36.

  32. Shimizu I. Antifibrogenic therapies in chronic HCV infection. Curr Drug Targets Infect Disord. 2001; 1:227-40.

  33. Yin M, Wheeler MD, Kono H, Bradford B, Gallucci RM, Luster MI, Thurman RG. Essential role of tumor necrosis factor alpha in alcoholic-induced liver injury in mice. Gastrenterol 1999; 117:942-52.

  34. Pinzani M. Hepatic stellate (Ito) cells: expanding roles for a liver specific pericyte. J Hepatol 1995; 22:700-6.

  35. Rosenbaum J, Blazejewski S. Regulation of Ito cell proliferation by soluble factors. J Hepatol 1995; 22:65-70.

  36. Rockey DC. The cell and molecular biology of hepatic fibrogenesis. Clinical and therapeutics implications. Clin Liver Dis 2000; 4:319-55.

  37. Schuppan D, Strobel D, Hahn EG. Hepatic fibrosis-Therapeutics strategies. Digestion 1998; 59:385-90.

  38. Bataller R, Brenner DA. Hepatic stellate cells as a target for the treatment of liver fibrosis. Semin Liver Dis 2001; 21:437-51.

  39. Safadi R, Friedman SL. Hepatic fibrosis – Role of hepatic stellate cell activation. Med Gen Med 2002; 15; 4:27.

  40. Mallat A, Preaux AM, Blazejewski S. Interferon alpha and gamma inhibit proliferation and collagen synthesis of human ito cells in culture. Hepatology 1995; 21:1003-10.

  41. Lu G, Shimizu I, Cui X, Itonaga M, Tamaki K, Fukuno H, Inoue H, Honda H, Ito S. Interferon alpha enhances biological defense activities against oxidative stress in cultured rat hepatocytes and hepatic stellate cells. J Med Invest 2002; 49:172-81.

  42. Rockey DC, Maher JJ, Jarnagin WR, Gabbiani G, Friedman SL. Inhibition of rat lipocyte activation in culture by interferon gamma. Hepatology 1992; 16:776-84.

  43. Abe S, Tabaru A, Ono M, Tai M, Narita R, Moriyama A, Otsuki M. High dose interferon-alpha therapy lowers the levels of serum fibrogenesis markers over 5 years in chronic hepatitis C. Hepatol Res 2003; 25:22-31.

  44. Manabe N, Chevallier M, Chossegros P. Interferon alpha therapy reduces liver fibrosis in chronic non A, non B hepatitis; a quantitative histological evaluation. Hepatology 1993; 18:1344-49.

  45. Camma C, Giunta M, Linea C. The effect of interferon on the liver in chronic hepatitis C; a quantitative evaluation of histology by meta-analysis. J Hepatol 1997; 26:1187-99.

  46. Rosenbloom J, Feldman G, Freundhich G, Jiménez SA. Transcriptional control of human diploid fibroblast collagen synthesis by interferon. Biochem Biophys Res Commun 1984; 123:365-72.

  47. Suou T, Hosho K, Kishimoto Y. Long–term decrease in serum N-terminal propeptide of type III procollagen in patients with chronic hepatitis C treated with interferon alpha. Hepatology 1995; 22:426-31.

  48. Guido M, Rugge M, Chemello L. Liver stellate cells in chronic viral hepatitis; the effect of interferon therapy. J Hepatol 1996; 24:301-7.

  49. Kirk AP, Jain S, Pocok S, Thomas HC, Sherlock S. Late results of the Royal Free Hospital prospective controlled trial of prednisone therapy in hepatitis B surface antigen negative chronic active hepatitis. Gut 1980; 21:78-83.

  50. Bodenheimer H, Shaffner F, Pezzullo J, Evaluation of colchicine therapy in primary biliary cirrhosis. Gastroenterology 1988; 95:124-9.

  51. Kaplan MM, Alling DW, Zimmerman HJ. A prospective trial of colchicine for primary biliary cirrhosis. N Engl J Med 1986; 315:1448-54.

  52. Castilla A, Prieta J, Fausto N. Transforming growth factors beta-1 and alpha in chronic liver disease: effect of interferon-alfa therapy. N Engl J Med 1991; 324:933-40.

  53. Poynard T, McHutchinson J, Davis GL. Impact of interferon alpha 2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C. Hepatology 200; 32:1187-99.

  54. Poynard T, McHutchinson J, Manns M, Trepo C, Linsay K, Goodman Z, Ling M, Albrecht J. Impact of pegylated interferon alpha 2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002; 122:1303-13.

  55. Poynard T, Moussali J, Ratziu V. Effect of interferon therapy in “non responder” patients with chronic hepatitis C, EASL International Consensus Conference on Hepatitis C. J Hepatol 1999; 31 (Suppl 1):178-83.

  56. Di Bisceglie AM, Thompson J, Smith-Wilkaitis N. Combination of interferon and ribavirin in chronic hepatitis C: re-treatment of nonresponder to interferon. Hepatology 2001; 33:704-7.

  57. Rodríguez Fragoso L., Alvarez R., Reyes Esparza J.A., Garcés A. M.E. Acetaldehyde increases the activity and gene expression of plasminogen activator activity in a hepatic stellate cell line. Toxicology 1999, 137:1-11.

  58. Bechade D, Oui B, Mayet F, Trouette H, Schouler L, Jouglen J, Raymond JM, Couzigou P. Appearance of hepatitis C virus replication and increase of aminotransferase activity after corticoid treatment of presumed autoimmune hepatitis. 2 cases. Gastroenterol Clin Biol 1996; 20:696-9.

  59. Angelico M, Cepparulo M, Barlattani A, Liuti A, Gentile S, Hurtova M, Ombres D, Guarascio P, Rocchi G, Angelico F. Unfavourable effects of colchicine in combination with interferon-alpha in the treatment of chronic hepatitis. Aliment Pharmacol Ther 2000; 14:1459-67.

  60. Floreani A, Colloredo G, Lobello S, Di Marco M, Popovic A, Naccarato R. Preliminary results of a two-center trial with colchicine for the treatment of chronic hepatitis B. Am J Gastroenterol 2001; 96:3451-2.

  61. Rodríguez L, Cerbón J, Muñoz-Moreno ML. Effects of colchicine and colchiceine in a biochemical model of liver injury and fibrosis. Archives of the Medical Research 1998, 29:109-17.

  62. Kershenobich D, Vargas F, García-Tsao G, Tamayo RP, Gent M, Rojkind M. Colchicine in the treatment of cirrhosis of the liver. N Engl J Med 1988; 318:1709-13.

  63. Mourelle M, Fraginals R, Rodríguez L, Favari L, Pérez-Alvarez V. Protective effect of colchiceine against acute liver damage. Life Science 1988; 45:891-900.

  64. Rodríguez L, Mourelle M, Pérez V, Cerbón AJ. Reduction of hepatic collagen synthesis by colchiceine in cirrhotic rat liver. Biochem Pharmacol. 1990; 9:157-63.

  65. Mourelle M, Favari L, Rodríguez L, Pérez V, Fraginals R. Colchiceine treatment prevents CCl4 induced rat liver cirrhosis. Biochem Pharmacol 1990; 9:165-9.

  66. Ala-Kokko L, Stenback F, Ryhannen L. Preventive effect of malotilate on dimethynitrosamine-induced liver fibrosis in the rat. J Lab Clin Med 1989; 113:177-83.

  67. Ala-Kokko L, Stenback F, Ryhannen L. Preventive effect of malotilate on carbon tetracloride induced liver damage and collagen accumulation in the rat. Biochem J. 1987; 246:503-9.

  68. Tanaka K, Honda M, Kuramochi T, Morioka S. Prominent inhibitory effects of transilast on migration and proliferation of collagen synthesis by vascular smooth muscle cells. Atherosclerosis 1994; 107:322-7.

  69. Ikeda H,Inao M, Fujiwara K. Inhibitory effect of transilast on activation and trasforming growth factor beta 1 expression in cultured rat stellate cells. Biochem Biophys Res Commun 1996; 227:322-7.

  70. Mancini R, Benedetti A, Jezequel AM. An interleukin-1 receptor antagonist decreases fibrosis induced by dimethylnitrosamine in rat liver. Virchows Arch 1994; 424:25-31.

  71. Forrt J, Oberti F, Pilette C. Antifibrotic and hemodynamic effect of the early and chronic administration of octreotide in two models of liver fibrosis in rats. Hepatology 1998; 28:1525-31.

  72. Karalis K, Mastorakos G, Chtousos GP, Tolis G. Somatostatin analogues suppress the inflammatory reaction in vivo. J Clin Invest 1994; 93:2000-6.

  73. Brown KE, Poulos JE, Li L. Effect of vitamin E suplementation on hepatic fibrogenesis in chronic dietary iron overload. Am J Physiol 1997; 272:G116-123.

  74. Kawada N, Seki S, Inoue M, Kuroki T. Effect of antioxidants, resveretrol, quercetin and N-acetylcysteine, on the functions of cultured rat hepatic stellate cells and Kupffer cells. Hepatology 1998; 27:1265-74.

  75. Ferenci P, Dragosics B, Dittrich H. Randomizedd controlled trials of sylimarin treatment in patients with cirrhosis of the liver. J Hepatol 1989; 9:105-10.

  76. Geerts A, Rogiers V, Sho-saiko-to. The right blend of traditional oriental medicine and liver cell biology. Hepatology 1999; 29:282-4.

  77. Boigk G, Stroedter L, Herbst H, Waldschmith J, Riecken EO. Sylimarin retards collagen accumulation in early and advanced biliary fibrosis secondary to complete bile duct obliteration in rats. Hepatology 1997; 26:643-9.

  78. Dehmlow C, Erhard J, De Groot H. Inhibition of Kupffer cells functions as an explanation for the hepatoprotective properties of silibinin. Hepatology 1996; 23:749-54.

  79. Pietrangelo A, Borella F, Casalgrandi G. Antioxidant activity of silybin in vivo during long-term iron overload in rats. Gastroenterology 1995; 109:1941-9.

  80. Friedman SL, Cytoquines and fibrogenesis. Semin Liver Dis 1999; 19:129-40.

  81. Qi Z, Atsuchi N, Ooshima A, Takeshita A, Ueno H Blockade of type beta transforming growth factor signaling prevents live fibrosis and dysfunction in the rat. Proc Natl Acad Sci USA 1999; 96:2345-9.

  82. Tsanf ML, Zhou L, Zheng BL. Characterization of recombinant soluble human transforming growth factor-beta receptor type II (rhTGF-beta sRII). Cytokine 1995; 7:389-97.

  83. Spearman M, Taylor WWR, Greenber AH, Wright JA. Antisense oligodeoxyribonucleotide inhibition of TGF-β 1 gene expression and alteration in growth and malignant properties of mouse fibrosarcoma cells. Gene 1994; 149: 25-9.

  84. Border WA, Noble NA, Yamamoto T. Natural inhibitor of transforming growth factor beta protects against scarring in experimental kidney disease. Nature 1992; 360:361-4.

  85. Roth S. Michel K, Gressner AM. (Latent) Transforming growth factor beta in liverparenchimal cells, its injury-dependent release, and paracrine effects on rat hepatic stellate cells. Hepatology 1998; 27:1003-12.

  86. Luscher TF, Wenzel RR. Endothelin and endhotelin antagonists: pharmacology and clinical implications. Agents Actions 1995; 45:237-53.

  87. Matsua Y, Matsumoto K, Yamada A. Preventive and therapeutic effects in rats of hepatocyte growth factor infusion on liver fibrosis/cirrhosis. Hepatology 1997; 26: 81-9.

  88. Ueki T, Kaneda Y, Tsutsui H. Hepatocyte growth factor gene therapy of liver cirrhosis in rats. Nat Med 1999; 5:226-30.

  89. Yasuda H, Imai E, Shiota A, Fujise N, Morinaga T. Antifibrogenic effect of a deletion variant of hepatocyte growth factor on liver fibrosis in rat. Hepatology 1996; 24:636-42.

  90. Unemori EN, Pickford LB, Salles AL. Relaxin induces an extracellular matrix-degrading phenotype in human lung fibroblast in vitro and inhibits lung fibrosis in a murine model in vivo. J Clin Invest 1996; 98:2739-45.

  91. Franklin TJ, Therapeutics approaches to organ fibrosis. Int J Biochem Cell Biol 1997; 29:79-89.

  92. Windmeir C, Gressner AM. Effect of pentoxifylline on the fibrogenic functions of cultured rat liver fat storing cells and myofibroblasts. Biochem Pharmacol 1996; 51: 577-84.

  93. Wu J, Zern MA. Hepatic stellate cells: a target for the treatment of liver fibrosis. J Gastroenterol. 2000; 35:665-72.

  94. Lee KS Cottam HB, Houglum K, Wasson DB, Carson D, Chojkier M. Pentoxifylline blocks hepatic stellate cell activation independently of phosphodiesterase inhibitory activity. Am J Physiol 1997; 273:G1094-100.

  95. Desmouliaere A, Xu G Costa AM, Youset IM, Gabianni G. Effects of pentoxifylline on early proliferation and phenotypic modulation of fibrogenic cells in two rat model of fibrosis and on cultured hepatic stellate cells. J Hepatol 1999; 3:621-31.

  96. Pinzani M, Gesualdo L, Sabbah GM, Abbound HE. Effects of platelet derived growth factor and other polypeptides mitogens on DNA synthesis and growth of cultured rat liver fat storing cells. J Clin Invest 1989; 84:1786-93.

  97. Marra F, Gentillini A, Pinzani M, Choudhury GG, Parola M, Herbst H. Phosphatidylinositol 3 kinase is required for platelet derived growth factor´s actions on hepatic stellate cells. Gastroenterology 1997; 112:1297-306.

  98. Marra F, Arriaghi MC, Fazi M, Caligiuri A, Pinzani M, Romanelli RG. Extracellular signal-regulated kinase activation differentially regulates platelet-derived growth factor´s actions in hepatic stellate cells, and is induced by in vivo liver injury in the rat. Hepatology 1999; 30:951-8.

  99. Arthur MJ, Iredali JP. Tissue inhibitor of metalloproteinases, hepatic stellate cells and liver fibrogenesis. J Gastroenterol Hepatol 1998; 13:S33-8.

  100. Unemori EN, Pickfors LB, Salles AL. Relaxin induces an extracellular matriz-degrading phenotype in human lung fibroblast in vitro and inhibits lung fibrosis in amurine model in vivo. J Clin Invest 1996; 98:2739-45.

  101. Prieto J, Quian C, Hernández-Alcoceba R, González-Aseguinolaza G, Mazzolini G, Sangro B, Kramer MG. Gene theraphy of liver diseases. Expert Opin Biol Ther 2004; 4: 1073-91.

  102. Armendariz-Borunda J. Genomic medicine in Mexico. Applications of gene therapy for cirrosis reversion. Hepatol 2002; 1:169-74.

  103. Chen M, Wang GJ, Diao Y, Xu RA, Xie HT, Xie HT, Li XY, Sun JG. Adeno-associated virus mediated interferon-gamma inhibits the progression of hepatic fibrosis in vitro and in vivo. World J Gastroentorol 2005; 11:4045-51.

  104. Aurisicchio L, Delmastro P, Salucci V, Paz OG, Rovere P, Ciliberto G, et al. Liver-specific alpha 2 interferon gene expression results in protection from induced hepatitis. J Virol 2000; 74:4816-4823.

  105. Hung KS, Lee TH, Chou WY, Wu CL, Cho CL, Lu CN, Jawan B, Wang CH. Interleukin-10 gene therapy reverses thioacetamide-induced liver fibrosis in mice. Bioche Biophys Res Commun 2005; 336:324-31.

  106. Kronke J, Kittler R, Buchholz F, Windisch MP, Pietschmann T, Bartenschlager R, et al. Alternative approaches for efficient inhibition of hepatitis C virus RNA replication by small interfering RNAs. J Virol 2004; 78: 3436-3446.

  107. Chiou HC, Lucas MA, Coffin CC, Banaszczyk MG, Ill CR, Lollo CP. Gene therapy strategies for the treatment of chronic viral hepatitis. Expert Opin Biol Ther 2001; 1: 629-639.

  108. Nakumuta M, Morizono S, Tsuruta S, Kohjima M, Kotoh K, Enjoji M. Remote delivery and expression of soluble type II TGF-beta receptor in muscle prevents hepatic fibrosis in rats. Int J Mol Med 2005; 16:59-64.

  109. Lin Y, Xie WF, Chen YX, Zhang X, Zeng X, Qiang H, Chen WZ, Yang XJ, Han ZG, Zhang ZB. Treatment of experimental hepatic fibrosis by combinational delivery of urokinasetype plasminogen activator and hepatocyte growth genes. Liver Int 2005; 25:796-807.




2020     |     www.medigraphic.com